Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 254.96M |
| Revenue (ttm) | 6.43M |
| Net Income (ttm) | -76.89M |
| Shares Out | 95.47M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 369,552 |
| Open | 2.33 |
| Previous Close | 2.28 |
| Day's Range | 2.23 - 2.33 |
| 52-Week Range | 1.98 - 4.50 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 6.40 (+181.9%) |
| Est. Earnings Date | Nov 8, 2021 |
About AVTX
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's dis...
Financial Performance
In 2020, AVTX's revenue was $6.70 million, a decrease of -0.77% compared to the previous year's $6.75 million. Losses were -$63.50 million, 295.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price forecast is 6.40, which is an increase of 181.94% from the latest price.
News
Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of ...
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapi...
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Cerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigati...
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of ...
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and I...
Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders Cerecor completes divestiture of non-core neurolo...
7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage
Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of t...
Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out
These 3 penny stocks made big moves in pre-market trading; are they worth it? The post Top Penny Stocks to Buy Moving in Premarket?
Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting L...
A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout
$230 million biopharmaceutical company Cerecor (CERC) may end up being the industry's biggest winner on Wall Street over the next six months. The post A Small Biotech Stock That Has All The Right Ingred...
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-00...
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare a...
Cerecor Reports 2020 Financial Results and Provides Business Updates
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of tre...
Cerecor to Present at Upcoming Investor Conferences
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...
Cerecor Shares Are Trading Higher On Positive CERC-002 Efficacy Data In COVID-19 Study
Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in hospitalized patients with COVID-19 assoc...
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and or...
Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceed...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializat...
Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...
Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...
Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still's Di...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refra...
Initial data anticipated in the first quarter of 2021 Initial data anticipated in the first quarter of 2021
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Def...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...